Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry

References

• www.who.int/mental_health/management/schizophrenia. World Health Organization. 2008. [Last accessed: 11-13-2008]
   Google Scholar
• Goeree R, Farahati F, Burke N, et al. The economic burden of schizophrenia in Canada in 2004. Curr Med Res Opin 2005;21:2017-28
   PubMed Web of Science ®Google Scholar
• Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004;30:279-93
   PubMed Web of Science ®Google Scholar
• Oliva-Moreno J, López-Bastida J, Osuna-Guerrero R, et al. The costs of schizophrenia in Spain. Eur J Health Econ 2006;7:179-84
   Google Scholar
• De Hert M, Thys E, Boydens J, et al. Health care expenditure on schizophrenia patients in Belgium. Schizophr Bull 1998;24:519-27
   PubMed Web of Science ®Google Scholar
• Knapp M, King D, Pugner K, et al. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry 2004;184:509-16
   PubMed Web of Science ®Google Scholar
• Almond S, Knapp M, Francois C, et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004;184:346-51
   PubMed Web of Science ®Google Scholar
• Wang X, Savage R BA, Rosenberg J, et al. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. J Psychiatr Res 2006;40:669-76
   PubMed Web of Science ®Google Scholar
• Lieberman J, Stroup S, McEvoy J, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009;166:152-63
   PubMed Web of Science ®Google Scholar
• Leucht S, Barnes T, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160:1209-22
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41
   PubMed Web of Science ®Google Scholar
• Lacro J, Dunn L, Dolder C, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909
   PubMed Web of Science ®Google Scholar
• Robinson D, Woerner M, Alvir J, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-7
   PubMed Web of Science ®Google Scholar
• McGlashan T, Johannessen J. Early detection and intervention with schizophrenia: rationale. Schizophr Bull 1996;22:201-22
   PubMed Web of Science ®Google Scholar
• Loebel A, Lieberman J, Alvir J, et al. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992;149:1183-8
   PubMed Web of Science ®Google Scholar
• Lieberman J, Sheitman B, Kinon B. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 1997;17:205-29
   PubMed Web of Science ®Google Scholar
• Kane J, Agugliab E, Altamurac A, et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 1998;8:55-66
   PubMed Web of Science ®Google Scholar
• Dolder C, Lacro J, Dunn L, et al Antipsychotic medication adherence: is there a difference between typical and atypical agents?. Am J Psychiatry 2002;159:103-8
   PubMed Web of Science ®Google Scholar
• Rainer M. Risperidone long-acting injection: a review of its long term safety and efficacy. Neuropsychiatr Dis Treat 2008;4:919-27
   PubMedGoogle Scholar
• Kane J, Eerdekens M, Lindenmayer J, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-32
   PubMed Web of Science ®Google Scholar
• Parellada E, Andrezina R, Milanova V, et al. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmacol 2005;19(5 Suppl):5-14
   PubMed Web of Science ®Google Scholar
• Fleischhacker W, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003;64:1250-7
   PubMed Web of Science ®Google Scholar
• Martin S, Libretto S, Pratt D, et al. Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone. Curr Med Res Opin 2003;19:298-305
   PubMed Web of Science ®Google Scholar
• Lindenmayer J, Eerdekens E, Berry S, et al. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004;65:1084-9
   PubMed Web of Science ®Google Scholar
• Marinis T, Saleem P, Glue P, et al. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry 2007;40:257-63
   PubMed Web of Science ®Google Scholar
• Janssen. www.risperdalconsta.com/risperdalconsta/index.html. 2008
   Google Scholar
• Guy W. Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV, 4th edn. Washington: American Psychiatric Association, 1994
   Google Scholar
• McGlashan T. The profiles of clinical deterioration in schizophrenia. J Psychiatr Res 1998;32:133-41
   PubMed Web of Science ®Google Scholar
• Olivares J, Rodriguez-Martinez A, Burón J, et al. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 2008;6:41-53
   PubMedGoogle Scholar
• Olivares J, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009; In press, available online
   PubMedGoogle Scholar
• Niaz O, Haddad P. Thirty-five months' experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand 2007;116:36-46
   PubMed Web of Science ®Google Scholar
• Kane J, Leucht S, Carpenter D, et al. Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003;64(Suppl 12):5-48
   PubMed Web of Science ®Google Scholar